Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. It is not yet known whether gemcitabine and erlotinib are more effective when given
alone or together in treating non-small cell lung cancer.
PURPOSE: This randomized phase II trial is studying gemcitabine and erlotinib to compare how
well they work when given alone or together as first-line therapy in treating older patients
with stage IIIB or stage IV non-small cell lung cancer.